Navigation Links
Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
Date:9/4/2007

Results Further Validate Lipidomic-Based Therapeutics as an Emerging Area

of Drug Discovery

SAN DIEGO, Sept. 4 /PRNewswire-FirstCall/ -- Lpath, Inc. (OTC Bulletin Board: LPTN), the category leader in therapeutic agents against bioactive lipids, reported positive results in several murine models of human cancer and AMD with Lpathomab(TM), the company's mouse monoclonal antibody against LPA (lysophosphatidic acid). These results confirm the expected potent anti-angiogenic and anti-metastatic actions of Lpathomab. Lpathomab was created using Lpath's proprietary ImmuneY2(TM) platform technology.

Based on this positive outcome, Lpath will collaborate with DataMabs of London, England, to humanize Lpathomab to create a lead antibody for pre- clinical development.

LPA is a bioactive lipid long recognized as a significant promoter of cancer-cell growth and metastasis in a broad range of tumor types, as well as a significant contributor to neuropathic pain.

"Humanizing our Lpathomab antibody is a vital next step in moving the project into the clinic," said Genevieve Hansen, Ph.D., Lpath's vice president of research. "We've had great success in the past working with DataMabs and look forward to working with them again on our Lpathomab project."

This achievement with Lpathomab comes on the heels of Lpath's success with its Sphingomab(TM) program. Sphingomab is an antibody against another bioactive lipid, S1P. Lpath humanized the antibody in 2006 and plans to file an IND in November of this year for the use of ASONEP(TM) (the systemic formulation of humanized Sphingomab) for the treatment of cancer. It also plans to file a second IND early next year for the use of iSONEP(TM) (the ocular formulation of humanized Sphingomab) for the treatment of AMD. The company plans to submit an IND filing for the use of humanized Lpathomab in 2009.

Dr. Roger Sabbadini, the founder and CSO of Lpath, commented, "These excitin
'/>"/>

SOURCE Lpath, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
7. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
8. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
9. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2008).../- Simcere,Pharmaceutical G...plier of,branded generic pharmaceuticals and manuf...t Endu (also known as Endostar) in China,announce...udy., At the request of the SFDA, Simcere initiat...he safety and therapeutic efficacy of Endu, a modi...
(Date:9/3/2008)...sults from chronically infected Hepatitis C,patien...ned earlier in 2008, - Study is the first to sho... antiviral effect of therapeutic Hepatitis C vacci... move into a second generation, vaccine formulate... TLR activation, VI...
(Date:9/3/2008)...NEVA, Sept. 3 /- Artelis SA and,Selex... monoclonal antibody,production with the achieveme...ter. This record level was accomplished by applyin...erformance stable Selexis CHO,production cell line...at,Selexis SA using their proprietary Selexis Gene...
(Date:9/3/2008)...Multaq(R) (dronedarone) decreased the risk of,stro...trial flutter already adequately trea... Sept. 3 /- The results of ...udy were presented today at,the clinical trial upd...congress 2008, in Munich, Germany. Previous result...
Breaking Medicine Technology:Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Nosefrida Nasal Aspirator A Parents Alternative to Medicines on the Verge of FDA Ban 2978 1Nosefrida Nasal Aspirator A Parents Alternative to Medicines on the Verge of FDA Ban 2978 2Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai 2975 1Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai 2975 2Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2973 1Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2973 2HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 1HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 2HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 3
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...tem reserachers have identified a key receptor tha...e treatment of acute respiratory distress syndrome... a life-threatening condition. The receptor is s...ht, smell and taste (G-protein coupled receptors) ...
...doss urged the Prime Minister Mr. Man Mohan Singh ... smoking in the films and television. // With the ...ing failing to reach consensus on modalities for i...ss, the minister approached Prime Minister Manmoha...
...rchers might be able to isolates molecule that wou...ory.// The revolutionary study has been done indep...Children's Hospital Boston and they have identifie... how neurons change as a result of individual expe...
...he Bihar government on Wednesday for neglecting th...hief Minister of Bihar Mr. Nitish Kumar gave the n...which was carried out with immediate effect. Last...issed three medical officers and initiated departm...
Other Medicine News:
PacePath is a comprehensive anatomic pathology software system that is the culmination of more than five years of development and testing by leading industry experts.
Velocity works cooperatively with LabSofts LabNet LIS, allowing the convenience of 24-hour access to information from satellite lab locations, hospitals, physician offices and even homes.
...eld (130" x 85") allows the surgeon to view the pa...hile remaining in the sterile field. , ,Electroca...ling cords while maintaining longer cord length st...large particle screen accommodates the larger inci...
The Bohn™ Extremity Drape is economically sound - this single extremity drape replaces two large antimicrobial impregnated "Vi-Drapes" ...the traditional "shower curtain"...and your current "ex
Medicine Products: